hide message

Welcome to the Resource Centre

We make it our mission to work with advocates in civil society, business and government to address inequalities of power, seek remedy for abuse, and ensure protection of people and planet.

Both companies and impacted communities thank us for the resources and support we provide.

This is only possible because of your support. Please make a donation today.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

Indian and Chinese drug companies sign pact with Clinton Foundation for low-priced malaria drugs

Get RSS feed of these results

All components of this story

Article
18 July 2008

Deal Seeks to Provide Malaria Medicine at Low Prices

Author: Donald McNeil, New York Times

The Clinton Foundation announced Thursday that it had brokered an agreement among several drug makers that it hopes will assure a steady supply of a crucial malaria medicine at reasonable prices for the world’s poor... In 2004, when international donors agreed to pay for artemisinin-based drug cocktails, the price of the raw material soared... Novartis, then the only company with an artemisinin-based drug approved by the World Health Organization, absorbed the losses, and generic drug makers were scared away from the field... The complex deal announced Thursday includes two Chinese suppliers of artemisinin, two Indian companies that process it into derivatives like artesunate, and two more Indian companies, Cipla and Ipca Laboratories, that produce finished pills.

Read the full post here

Article
18 July 2008

Indian firms, Clinton Foundation sign deal on malaria drugs

Author: Indo Asian News Service

Four Indian and two Chinese companies will cut the price of a key malaria drug and control rates of a vital ingredient following a pact signed Thursday with the US-based Clinton Foundation…The Indian companies are generic drug firms Cipla and IPCA Laboratories… and Calyx and Mangalam Drugs…China’s Holleypharm and PIDI Standard grow the plants…“This agreement will reduce the prices for ACT drugs by 30 percent,” [former U.S. President Bill] Clinton said while announcing the deal...The lower prices for the ACT drugs will be available to the 69 countries in Africa, Asia, Latin America and the Caribbean that make up the Clinton HIV-AIDS Initiative (CHAI) purchasing consortium…[refers also to Novartis]

Read the full post here

Article
+ Français - Hide

Author: La Voix de l'Amerique

L’ancien président américain Bill Clinton affirme que six compagnies pharmaceutiques indiennes et chinoises ont accepté de réduire le prix d’un des principaux traitements contre la malaria. L’accord a été facilité par la fondation caritative de M. Clinton, qui est basée à New York... [L]e nouvel accord signifie que les prix des médicaments ACT devraient nettement baisser dans 69 pays d’Afrique, d’Asie, d’Amérique du Sud et de la mer des Caraïbes. Il implique Holleypharm et PIDI Standard, deux compagnies pharmaceutiques chinoises... Les quatre autres sociétés qui ont accepté de participer au projet fabriquent le médicament, et sont basées en Inde. Il s’agit de Cipla, IPCA Laboratories, Calyx et Mangalam Drugs.

🚫Read the full post here

Article
17 July 2008

Clinton Foundation Sets Up Malaria-Drug Price Plan - Aim Is to Stabilize Fluctuating Prices, Boost Availability

Author: Mark Schoofs, Wall Street Journal

Former President Bill Clinton's foundation is set to unveil a pricing agreement Thursday that it hopes will make malaria drugs available to millions of poor people... First-line malaria drugs -- known as ACTs, for artemisinin-based combination therapies -- present a tricky problem: the volatile cost of the powerful antimalarial plant extract artemisinin... Such instability makes it difficult for those in the market -- from artemisinin producers to pharmaceutical companies to the health ministries that often buy the drugs -- to plan. That can make pharmaceutical companies wary of reducing prices for fear of another price spike and deter generic-drug makers from entering the market and fostering more-competitive pricing. The agreement Mr. Clinton plans to announce aims to limit price fluctuations... Scheduled to join Mr. Clinton at the presentation is Novartis AG Chief Executive Daniel Vasella. The Swiss drug company has been supplying the overwhelming majority of ACTs in the developing world...at an overall loss that Dr. Vasella said exceeds $100 million, including research-and-development costs. Mr. Clinton is expected to thank Novartis for supplying the drug and for not raising the price despite the artemisinin price increase.

Read the full post here